Mercer Global Advisors’s Heron Therapeutics HRTX Stock Holding History

Mercer Global Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.1K	Buy	68,291 +27,253	+66%	+$21.9K	﹤0.01%	3561
2026 Q1	$32.8K	Buy	41,038 +27,658	+207%	+$32K	﹤0.01%	3161
2025 Q4	$17.4K	Sell	13,380 -13,329	-50%	-$16.5K	﹤0.01%	2826
2025 Q3	$33.7K	Buy	+26,709	New	+$42.3K	﹤0.01%	2607
2020 Q1	–	Sell	-41,471	Closed	-$975K	–	1167
2019 Q4	$975K	Buy	41,471 +2,156	+5%	+$47.7K	0.02%	534
2019 Q3	$727K	Buy	39,315 +2,563	+7%	+$47.2K	0.02%	576
2019 Q2	$683K	Sell	36,752 -1,800	-5%	-$36K	0.02%	573
2019 Q1	$942K	Buy	+38,552	New	+$1.01M	0.03%	429

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Mercer Global Advisors's HRTX Position: Q2 2026 in Review

Mercer Global Advisors increased its Heron Therapeutics (HRTX) stake by 66% in Q2 2026, buying an estimated $21.9K and bringing the position to 68,291 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

Mercer Global Advisors first reported a position in HRTX in Q1 2019 and has held it in 8 quarters since. The position peaked at $975K in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Mercer Global Advisors held 68,291 shares of Heron Therapeutics worth $29.1K as of Q2 2026.
Mercer Global Advisors bought 27,253 Heron Therapeutics shares in Q2 2026, an estimated $21.9K.
Heron Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3561 holding.
Mercer Global Advisors first reported a position in Heron Therapeutics in Q1 2019 and has held it in 8 quarters since.
Mercer Global Advisors's Heron Therapeutics position peaked at $975K in Q4 2019.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.